Related Experiment Video

Updated: Aug 11, 2026

Implantation of the Syncardia Total Artificial Heart
16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

An angiotensin-converting enzyme inhibitor improves left ventricular systolic and diastolic function in

H I Karvounis1, T A Zaglavara, G E Parharidis

  • 1First Department of Cardiology, Aristotle University, Thessaloniki, Greece.

American Heart Journal
|February 15, 2001
PubMed

Insights

Long-term enalapril treatment improved cardiac function in beta-thalassemia major patients. This study demonstrated enhanced left ventricular (LV) systolic and diastolic performance, offering potential benefits for managing cardiac complications in this population.

Area of Science:

  • Cardiology
  • Hematology

Background:

  • Cardiac complications are a leading cause of mortality in beta-thalassemia major.
  • Diastolic dysfunction is an early indicator of cardiac issues in asymptomatic patients with mild left ventricular (LV) systolic impairment.

Purpose of the Study:

  • To evaluate the long-term effects of enalapril on left ventricular (LV) performance in beta-thalassemia major patients.
  • To specifically assess the impact on diastolic LV function, an early marker of cardiac dysfunction.

Main Methods:

  • Echocardiography was employed to monitor changes in standard M-mode and Doppler indices.
  • A novel Doppler index for combined systolic and diastolic LV performance was utilized.

Main Results:

  • Enalapril treatment led to a significant decrease in LV end-systolic dimensions (LVESD) and a significant increase in LV fractional shortening (LVFS).
  • Post-treatment, patients showed improvements in diastolic function, indicated by a decreased E/A ratio and prolonged E-wave deceleration time.
  • A composite Doppler index also showed significant improvement after enalapril administration.

Conclusions:

  • Enalapril is well-tolerated in beta-thalassemia major patients with LV dysfunction.
  • Echocardiographic evidence shows significant improvements in both LV systolic and diastolic function.
  • Further research is needed to determine if these functional improvements translate to enhanced long-term prognosis and survival.
Abstract

More Related Videos

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies11:59

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Published on: September 6, 2017

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...